Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908036 | 0.80 | PLD1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4901832 | 0.79 | KDM4A (0.43) | DRD4 | |
| SCHEMBL4910119 | 0.78 | NPC1 (0.47) | DRD4DRD2DRD3CNR1 | |
| SCHEMBL18114683 | 0.76 | MAPT (0.42) | — | |
| SCHEMBL30818742 | 0.76 | MAPT (0.42) | — | |
| SCHEMBL3088832 | 0.71 | DRD4 (0.54) | DRD4DRD2DRD3PHGDHSLC2A1 | |
| SCHEMBL5274973 | 0.70 | PARP1 (0.41) | DRD4DRD2DRD3CNR1 | |
| SCHEMBL23277098 | 0.70 | KDM4E (0.58) | DRD4DRD2DRD3CNR1HTR2A | |
| SCHEMBL14183770 | 0.68 | RECQL (0.53) | DRD4DRD2DRD3RECQL | |
| SCHEMBL829177 | 0.64 | AR (0.65) | DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1841769-A2 | PURINE DERIVATIVES COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AGAINST CANCER | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006075094-A2 | PURINE DERIVATIVES COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AGAINST CANCER | AVENTIS PHARMA S.A (FR) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | TYMP, HPRT1, IMPDH1 | DRD4 2822/4885TACR3 4240/4885DRD2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.